Curis, Inc. (CRIS)
-NasdaqGM 3.78 
0.08(2.16%) May 23, 4:00PM EDT|After Hours
:
3.78 0.00 (0.00%) May 23, 4:37PM EDT
| Prev Close: | 3.70 |
|---|
| Open: | 3.65 |
|---|
| Bid: | 3.10 x 100 |
|---|
| Ask: | 4.14 x 400 |
|---|
| 1y Target Est: | 6.86 |
|---|
| Beta: | 2.1 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 3.60 - 3.81 |
|---|
| 52wk Range: | 2.66 - 5.51 |
|---|
| Volume: | 573,909 |
|---|
| Avg Vol (3m): | 579,729 |
|---|
| Market Cap: | 304.43M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.30 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Curis to Present at the Deutsche Bank 38th Annual dbAccess Health Care ConferenceGlobeNewswire(Wed, May 22)
- American Society Of Clinical Oncology Abstracts Point To Potential Profitsat Seeking Alpha(Tue, May 21)
- CURIS INC FinancialsEDGAR Online Financials(Fri, May 17)
- Curis Announces Presentation of CUDC-427 and Erivedge(R) Clinical Results at ASCO Annual MeetingGlobeNewswire(Thu, May 16)
- 10 ASCO '13 Abstracts You Can Read Right Nowat TheStreet(Wed, May 15)
- Three of WellPoint's directors resign for personal reasonsat Reuters(Mon, May 13)
- Curis Announces Approval of Erivedge(R) in AustraliaGlobeNewswire(Fri, May 10)
- CURIS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Incremental Changes in Regulatory Environment Beneficial to Development-Stage Biotech Companies Due to Emphasis on Closer Working Relationships with the FDA and Drug SponsorsWall Street Transcript(Wed, May 1)
- Curis Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, Apr 30)
- Curis Earnings: Here’s Why Investors Don’t Like These Resultsat Wall St. Cheat Sheet(Tue, Apr 30)
- CURIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal OfficerEDGAR Online(Tue, Apr 30)
- Q1 2013 Curis, Inc. Earnings Release - Before Market OpenCCBN(Tue, Apr 30)
- Curis Reports First Quarter 2013 Financial ResultsGlobeNewswire(Tue, Apr 30)
- Positive News for RocheZacks(Mon, Apr 29)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 39.80 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.22 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.02 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Curis, Inc. engages in the research, development, and commercialization of cancer therapeutics. Its principal product is Erivedge capsule for treatment of adults with basal cell carcinoma (BCC) that has spread to other parts of the body or that ha...
View More